Table 3.
Susceptibility distribution of 403 clinical isolates of C. difficile by genotypes to four agents with MIC interpretive breakpoints by the Clinical and Laboratory Standards Institute (6)
| Agent | No. (%) of isolates for each genotype |
|||||
|---|---|---|---|---|---|---|
|
tcdA+
tcdB+
cdtA+
cdtB+ (n = 39 isolates) |
tcdA+
tcdB+
cdtA−
cdtB− (n = 194 isolates) |
tcdA−
tcdB−
cdtA−
cdtB− (n = 170 isolates) |
||||
| Susceptible | Resistant | Susceptible | Resistant | Susceptible | Resistant | |
| Metronidazolea | 39 (100) | 0 (0) | 194 (100) | 0 (0) | 170 (100) | 0 (0) |
| Vancomycinb | 39 (100) | 0 (0) | 193 (99) | 1 (1) | 169 (99) | 1 (1) |
| Clindamycina | 8 (21) | 24 (62) | 14 (7) | 151 (78) | 33 (19) | 121 (71) |
| Moxifloxacina | 29 (74) | 10 (26) | 157 (81) | 33 (17) | 136 (80) | 29 (17) |
a
MIC breakpoints applied were those recommended for anaerobes by the Clinical and Laboratory Standards Institute (CLSI-2007, M11-A7) (6).
b
For vancomycin there are no CLSI-recommended MIC breakpoints. Breakpoints are those recommended by The European Committee on Antimicrobial Susceptibility Testing (EUCAST) (13).